This clinical trial is focused on studying a condition known as Generalized Myasthenia Gravis, specifically in patients who do not have certain antibodies called acetylcholine receptor binding antibodies. This condition is a chronic autoimmune disorder that causes muscle weakness. The study will evaluate a treatment called Efgartigimod IV, which is a medication given through an intravenous infusion. This means the medicine is delivered directly into the bloodstream through a vein. The purpose of the study is to determine how effective and safe this treatment is compared to a placebo in managing the symptoms of this condition.

Participants in the study will receive either the Efgartigimod IV treatment or a placebo. The study is designed to be double-blinded, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are unbiased. The study will follow a structured plan over a period of time, during which participants will be monitored for changes in their symptoms and any side effects they may experience.

The trial aims to provide valuable information about the potential benefits of Efgartigimod IV for people with Generalized Myasthenia Gravis who are seronegative for acetylcholine receptor binding antibodies. By comparing the effects of the treatment to those of a placebo, researchers hope to better understand how this medication can help manage the condition and improve the quality of life for those affected. Participants will be closely observed throughout the study to ensure their safety and to gather comprehensive data on the treatment’s impact.